Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review
Open Access
- 29 April 2022
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0267808
Abstract
Aim: Long acting injectable (LAI) antipsychotics are an alternative to oral antipsychotic (OAP) treatment and may be beneficial for patients in the early stages of schizophrenia. This study aims to provide a comprehensive review on the efficacy of first-generation and second-generation LAI antipsychotics in recent-onset, first-episode, and early psychosis patients.Methods: MEDLINE, EMBASE, PsycINFO, and Web of Science Core databases were used to search for studies that used LAIs in early psychosis patients. Studies published up to 06 Jun 2019 were included with no language restrictions applied. Inclusion criteria were a diagnosis of schizophrenia or related disorder, where patients were in their first episode or had a duration of illness ≤5 years.Results: 33 studies were included: 8 RCTs, 4 post-hoc analyses, 2 case reports, and 19 naturalistic studies. The majority of studies evaluated risperidone LAIs (N = 14) and paliperidone palmitate (N = 10), while the remainder investigated fluphenazine decanoate (N = 3), flupentixol decanoate (N = 2), and aripiprazole (N = 1). Two studies did not specify the LAI formulation used, and one cohort study compared the efficacy of multiple different LAI formulations.Conclusions: While the majority of data is based on naturalistic studies investigating risperidone LAIs or paliperidone palmitate, LAIs may be an effective treatment for early psychosis patients in terms of adherence, relapse reduction, and symptom improvements. There is still a need to conduct more high quality RCTs that investigate the efficacy of different LAI formulations in early psychosis patients.Keywords
This publication has 64 references indexed in Scilit:
- Clinical outcomes of long‐acting risperidone in recent versus long‐term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e‐STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES)Early Intervention in Psychiatry, 2013
- Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with OlanzapinePLOS ONE, 2013
- Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and ConsSchizophrenia Research and Treatment, 2012
- Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaNeuropsychiatric Disease and Treatment, 2012
- Guidelines for rating Global Assessment of Functioning (GAF)Annals of General Psychiatry, 2011
- Risperidone long-acting therapy in stable patients with recently diagnosed schizophreniaInternational Clinical Psychopharmacology, 2010
- Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studiesClinical Therapeutics, 2008
- Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry, 2008
- Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset PsychosisJournal of Clinical Psychopharmacology, 2008
- Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectableJournal of Psychopharmacology, 2005